Abstract
One of the critical points in the pathogenesis of aortic aneurysms (AAs) is the disruption of the balance between vascular extracellular matrix (ECM) deposition and degradation. AAs are common features in some genetically determined diseases of the connective tissue, such as Marfan and Ehlers-Danlos. Acquired factors determining an enhanced inflammatory state of the arterial wall also play a key role. Previous studies have determined the role of tumor growth factor β (TGF-β); as a principal mediator of the pathogenesis of the alterations of the arterial wall homeostasis in AAs. The medical management of any AA is mainly focused on the use of pharmacological agents that reduce hemodynamic stress of the aortic wall, since hypertension is the major risk factor for the enlargement and rupture of the AAs. However, this is far from being a comprehensive pathophysiology-based therapeutic approach. Drugs potentially able to reduce the release of TGF-β may play a role in the pathogenesis of the AAs. They work by improving matrix repair, decreasing the proteolytic pattern and inhibition of angiotensin-converting enzyme (ACE) as well as preventing angiotensin II-induced angiotensin type-1 receptor (AT1R) activation. A new pathophysiology-based therapeutic approach, involving the mechanisms leading to the rupture of the AAs, could represent an additional tool in combination with the current established antihypertensive therapy.
Keywords: Pathophysiology, medical therapy, aortic aneurysms, atherosclerosis, insulin resistance, metalloproteinases, tumor growth factor ß, angiotensin-converting enzyme, hypertension, inflammation
Current Vascular Pharmacology
Title: Medical Therapy of Aortic Aneurysms: A Pathophysiology-Based Approach
Volume: 9 Issue: 5
Author(s): Giovanna Muscogiuri, Gian Pio Sorice, Devjit Tripathy, Alberto O. Chavez, Alberto Davalli, Richard A. Lange and Franco Folli
Affiliation:
Keywords: Pathophysiology, medical therapy, aortic aneurysms, atherosclerosis, insulin resistance, metalloproteinases, tumor growth factor ß, angiotensin-converting enzyme, hypertension, inflammation
Abstract: One of the critical points in the pathogenesis of aortic aneurysms (AAs) is the disruption of the balance between vascular extracellular matrix (ECM) deposition and degradation. AAs are common features in some genetically determined diseases of the connective tissue, such as Marfan and Ehlers-Danlos. Acquired factors determining an enhanced inflammatory state of the arterial wall also play a key role. Previous studies have determined the role of tumor growth factor β (TGF-β); as a principal mediator of the pathogenesis of the alterations of the arterial wall homeostasis in AAs. The medical management of any AA is mainly focused on the use of pharmacological agents that reduce hemodynamic stress of the aortic wall, since hypertension is the major risk factor for the enlargement and rupture of the AAs. However, this is far from being a comprehensive pathophysiology-based therapeutic approach. Drugs potentially able to reduce the release of TGF-β may play a role in the pathogenesis of the AAs. They work by improving matrix repair, decreasing the proteolytic pattern and inhibition of angiotensin-converting enzyme (ACE) as well as preventing angiotensin II-induced angiotensin type-1 receptor (AT1R) activation. A new pathophysiology-based therapeutic approach, involving the mechanisms leading to the rupture of the AAs, could represent an additional tool in combination with the current established antihypertensive therapy.
Export Options
About this article
Cite this article as:
Muscogiuri Giovanna, Pio Sorice Gian, Tripathy Devjit, O. Chavez Alberto, Davalli Alberto, A. Lange Richard and Folli Franco, Medical Therapy of Aortic Aneurysms: A Pathophysiology-Based Approach, Current Vascular Pharmacology 2011; 9 (5) . https://dx.doi.org/10.2174/157016111796642724
DOI https://dx.doi.org/10.2174/157016111796642724 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Advancements in Arterial Stiffness: Novel Therapeutic Frontiers
Arterial stiffness, a hallmark of cardiovascular disease, poses significant challenges in contemporary healthcare. This thematic issue delves into the multifaceted landscape of arterial stiffness and explores cutting-edge therapeutic interventions aimed at mitigating its adverse effects. Within these pages, readers will find a comprehensive overview of the mechanisms underlying arterial stiffness, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Current Genomics in Cardiovascular Medicine
Current Genomics Cardiovascular Magnetic Resonance for Evaluation of Heart Involvement in ANCA-Associated Vasculitis. A Luxury or a Valuable Diagnostic Tool?
Inflammation & Allergy - Drug Targets (Discontinued) Cellular Mechanisms of Bypass Vein Graft Arterialization and Approaches to Attenuate Graft Remodeling
Vascular Disease Prevention (Discontinued) Multidrug-Resistance (MDR) Proteins Develops Refractory Epilepsy Phenotype:Clinical and Experimental Evidences
Current Drug Therapy Non-Steroidal LXR Agonists; An Emerging Therapeutic Strategy for the Treatment of Atherosclerosis
Recent Patents on Cardiovascular Drug Discovery Agonists of the Tissue-Protective Erythropoietin Receptor in the Treatment of Parkinson’s Disease
Current Topics in Medicinal Chemistry A Direct Correlation between Red Blood Cell Indices and Cognitive Impairment After Aneurysmal Subarachnoid Hemorrhage (aSAH)
Current Neurovascular Research Autoimmune Pancreatitis and Diagnostic Criteria
Current Immunology Reviews (Discontinued) Sirolimus Eluting Stent: A New Era in Interventional Cardiology?
Current Pharmaceutical Design Pathophysiology of Cardiovascular Diseases and the Role of Vitamins, and Herbal Extracts in the Reduction of Cardiovascular Risks
Cardiovascular & Hematological Agents in Medicinal Chemistry Animal Galectins and Plant Lectins as Tools for Studies in Neurosciences
Current Neuropharmacology Molecular Imaging of Vascular Inflammation
Current Pharmaceutical Design Endovascular Therapies for Type B Aortic Dissection
Cardiovascular & Hematological Disorders-Drug Targets Safety and Efficacy of Intracoronary Human Umbilical Cord-Derived Mesenchymal Stem Cell Treatment for Very Old Patients with Coronary Chronic Total Occlusion
Current Pharmaceutical Design Comprehensive in silico Study of GLUT10: Prediction of Possible Substrate Binding Sites and Interacting Molecules
Current Pharmaceutical Biotechnology Pyridinoline, A Collagen Crosslink, As a Biochemical Marker for Arthritis
Current Rheumatology Reviews Recent Advances in Nanobiotechnology for the Treatment ofNon-Hodgkin’s Lymphoma
Mini-Reviews in Medicinal Chemistry Beta-Blockers and Abdominal Aortic Aneurysm Growth: A Systematic Review and Meta-Analysis
Current Cardiology Reviews Renal Nerve Ablation for Hypertensive Patients with Chronic Kidney Disease
Current Vascular Pharmacology Association of Rebleeding and Delayed Cerebral Ischemia with Long-termMortality Among 1-year Survivors After Aneurysmal Subarachnoid Hemorrhage
Current Neurovascular Research